Genotypic characterization, antimicrobial susceptibility and virulence determinants of Campylobacter jejuni and Campylobacter coli isolated from pastured poultry farms

Antimicrobial resistance in Campylobacter spp. focussing on C. jejuni and C. coli - A Narrative Review

OBJECTIVES

Campylobacter species represent one of the leading causes of human foodborne infections, including gastroenteritis and bloody diarrhoea. Overuse of antibiotics in veterinary, agriculture, and humans has led to an increase in multidrug antimicrobial resistance (AMR). Fluoroquinolones and macrolides resistant Campylobacters are WHO and CDC priority pathogens, with fluoroquinolone resistance doubling in the past 20 years, complicating treatment.

METHODS

Published studies relating to AMR and associated molecular mechanisms in both Campylobacter jejuni and C. coli from animals, humans and environment (1981 - 2024), were retrieved from PubMed and Google Scholar using relevant keywords. In addition, genomic analyses of publicly available C. jejuni and C. coli genomes along with multi-locus sequence typing results from the PubMLST database were used to analyse these AMR determinants and their phylogenomic relationships. Review articles were excluded from the analyses.

RESULTS

A total of 429 research papers were reviewed to get insights into multidrug resistance in C. jejuni and C. coli. Fluroquinolone resistance has been predominantly associated with international travel. The gyrA subunits were associated with ecological niches and overall, it is suggestive that C. coli might be the donor. A positive synergism was observed between cmeA gene expression and quinolone resistance. Additionally, the results speculated the possibility of horizontal gene transfers in chromosomal resistance clusters between C. coli and C. jejuni.

CONCLUSION

This review indicated significant concern of multidrug resistance in C. jejuni and C. coli. This requires continent-wide surveillance and research for standard practices to achieve effective antimicrobial stewardship.

Campylobacter jejuni ST353 and ST464 cause localized gut inflammation, crypt damage, and extraintestinal spread during large- and small-scale infection in broiler chickens

Campylobacter infections in humans and chickens are a significant burden to health services and the poultry industry. In the UK, over 75% of chicken products are Campylobacter-positive at retail, but the knowledge of the mechanisms responsible for extraintestinal spread into edible tissues remains incomplete. This work aimed to establish if two chicken-associated lineages of Campylobacter jejuni, ST353 and ST464, have the potential for extraintestinal spread. Large- and small-scale chicken colonization trials investigated the infection biology of C. jejuni ST353 (three strains) and ST464 (four strains). Both lineages strongly colonized the ileum and ceca and were detected in liver and spleen. C. jejuni ST353 and ST464 spleen load were significantly increased compared to C. jejuni M1 controls. Immune responses in cecal tonsils exhibited early induction of IFN-γ and suppressed TGFβ at 7 days post-infection with C. jejuni ST464. Histochemistry of gut tissue demonstrated significant decreases in intestinal crypt depth in ileal tissue with increasing severity relative to Campylobacter lineage, M1 Collapse

Key Words

• Campylobacter jejuni
• biomarkers
• broiler chicken
• cecal tonsil-derived cytokine production
• crypt depth
• gut damage
• gut health
• in vivo chicken infection

Collapse

MESH Headings

• Animals
• Chickens/microbiology
• Campylobacter jejuni/physiology
• Campylobacter jejuni/genetics
• Campylobacter Infections/veterinary
• Campylobacter Infections/microbiology
• Campylobacter Infections/pathology
• Campylobacter Infections/immunology
• Poultry Diseases/microbiology
• Poultry Diseases/pathology
• Poultry Diseases/immunology
• Cecum/microbiology
• Inflammation/microbiology
• Inflammation/veterinary
• Spleen/microbiology

Collapse

Grants

• BB019142/1 UKRI | Biotechnology and Biological Sciences Research Council (BBSRC)

Collapse

Affiliation(s)

Heather M. Chick Microbiology and Infectious Disease, Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom
Lisa K. Williams Microbiology and Infectious Disease, Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom Department of Animal and Agriculture, Hartpury University, Gloucester, United Kingdom
Nick Sparks Scotland’s Rural College (SRUC) Barony Campus, Dumfries, United Kingdom
Farina Khattak Monogastric Science Research Center, Scotland’s Rural College (SRUC), Edinburgh, United Kingdom
Paul Vermeij MSD Animal Health, Boxmeer, the Netherlands
Inge Frantzen MSD Animal Health, Boxmeer, the Netherlands
Mandy Peeters MSD Animal Health, Boxmeer, the Netherlands
Jetta J. E. Bijlsma MSD Animal Health, Boxmeer, the Netherlands
Daniel John Microbiology and Infectious Disease, Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom
Timothy Ogunrin Microbiology and Infectious Disease, Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom
Keioni Essex Microbiology and Infectious Disease, Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom
Caroline Cayrou Genetics, Genomics, and Cancer Sciences, University of Leicester, Leicester, United Kingdom
Venkateswarlu Kanamarlapudi Cellular Biology, Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom
Christopher D. Bayliss Genetics, Genomics, and Cancer Sciences, University of Leicester, Leicester, United Kingdom
Julian M. Ketley Genetics, Genomics, and Cancer Sciences, University of Leicester, Leicester, United Kingdom
Thomas J. Humphrey Microbiology and Infectious Disease, Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom
Steven P. Rushton School of Natural and Environmental Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
Thomas S. Wilkinson Microbiology and Infectious Disease, Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom

Collapse

Increasing rates of erm(B) and erm(N) in human Campylobacter coli and Campylobacter jejuni erythromycin-resistant isolates between 2018 and 2023 in France

Macrolides are the first-line compounds used for the treatment of campylobacteriosis. Macrolide resistance remains low in France, with mutations in 23S rDNA being the main associated resistance mechanism. However, two erythromycin methyltransferases have also been identified: erm(B), which is mainly described in animal reservoirs, and erm(N), which is strictly described in humans. In France, between 2018 and 2023, erythromycin-resistant Campylobacter species strains were systematically sequenced and analyzed via an in-house bioinformatics pipeline, leading to the identification of the resistomes, MLST and cgMLST, as well as the characterization of the source of contamination. In this study, the genomes of 280 erythromycin-resistant strains were sequenced over a 6-year period. The identification of erythromycin-associated resistance markers revealed a predominance of 23S rDNA mutations, in 90% of cases, but also erm-type methyltransferases in 10% of cases: 75% for erm(N) and 25% for erm(B). Over this period, an important increase in the rate of erm-positive isolates was observed: 2% in 2018 compared with 13% in 2023, with 10% for erm(N) and 3% for erm(B). erm(N) has been found exclusively within a CRISPR-Cas9 operon, whereas erm(B) has been found within diverse types of resistance genomic islands. Each erm(N)- or erm(B)-positive isolate had at least two other resistance markers (mostly ciprofloxacin, tetracycline, or ampicillin) and often carried aminoglycoside-associated resistance genes. The majority of the erm-positive isolates were obtained from chicken. The increasing rates of erm-positive and multiresistant isolates make the monitoring of erythromycin-resistant Campylobacter strains, specifically within the chicken meat production, a topic of serious importance.

Comparative Molecular Virulence Typing and Antibiotic Resistance of Campylobacter Species at the Human-Animal-Environment Interface

This study holds significant importance due to its focus on Campylobacter, the leading bacterial cause of gastroenteritis worldwide, responsible for ∼96 million cases each year. By investigating the prevalence of both Campylobacter jejuni and Campylobacter coli in humans, animals, and the environment, this research sheds light on the broader impact of these pathogens, which can harm both human and animal populations. Traditional microbiological methods were implemented followed by optimized multiplex polymerase chain reaction targeting 16S rDNA and virulence gene markers by using specific primers. The findings revealed that a total of 219 Campylobacter isolates were recovered from 528 collected specimens from human, animal, and environmental sources. Campylobacter species showed a prevalence of 41.5%, with C. jejuni accounting for 53% and C. coli for 47%. Antimicrobial resistance rates were high, with tetracycline at 89%, ceftriaxone at 75%, cefotaxime at 70%, erythromycin at 69%, nalidixic acid at 54%, ciprofloxacin at 39%, and gentamicin at 23%. Commonly prevalent virulence-associated genes observed in the Campylobacter were cadF at 93%, flaA at 91%, cdtB at 88%, cheY at 86%, sodB at 78%, and iamA at 32%. The study confirmed multidrug-resistant Campylobacter prevalence at the human-animal-environment interface, harboring virulence-associated genes with potential harm to humans. Data analysis showed a nonsignificant (p ≥ 0.05) correlation between virulence genes and antibiotic susceptibility. To effectively manage Campylobacter infections, a multifaceted strategy incorporating preventative interventions at different levels is required. This strategy should take into account practicability, effectiveness, and sustainability while strengthening surveillance systems and addressing the economics of disease prevention.

Consortium of Lactobacillus crispatus 2029 and Ligilactobacillus salivarius 7247 Strains Shows In Vitro Bactericidal Effect on Campylobacter jejuni and, in Combination with Prebiotic, Protects Against Intestinal Barrier Dysfunction

Background/Objectives:Campylobacter jejuni (CJ) is the etiological agent of the world's most common intestinal infectious food-borne disease, ranging from mild symptoms to fatal outcomes. The development of innovative synbiotics that inhibit the adhesion and reproduction of multidrug-resistant (MDR) CJ in animals and humans, thereby preserving intestinal homeostasis, is relevant. We have created a synbiotic based on the consortium of Lactobacillus crispatus 2029 (LC2029), Ligilactobacillus salivarius 7247 (LS7247), and a mannan-rich prebiotic (Actigen®). The purpose of this work was to study the in vitro anti-adhesive and antagonistic activities of the created synbiotic against MDR CJ strains, along with its role in preventing intestinal barrier dysfunction, which disrupts intestinal homeostasis. Methods: A complex of microbiological, immunological, and molecular biological methods was used. The ability of the LC2029 and LS7247 consortium to promote intestinal homeostasis in vitro was assessed by the effectiveness of controlling CJ-induced TLR4 activation, secretion of pro-inflammatory cytokines, development of intestinal barrier dysfunction, and production of intestinal alkaline phosphatase (IAP). Results: All MDR CJ strains showed marked adhesion to human Caco-2, pig IPEC-J2, chicken CPCE, and bovine BPCE enterocytes. For the first time, we found that the prebiotic and cell-free culture supernatant (CFS) from the consortium of LC2029 and LS7247 strains exhibit an additive effect in inhibiting the adhesion of MDR strains of CJ to human and animal enterocytes. CFS from the LC2029 and LS7247 consortium increased the permeability of the outer and inner membranes of CJ cells, which led to extracellular leakage of ATP and provided access to the peptidoglycan of the pathogen for the peptidoglycan-degrading bacteriocins nisin and enterolysin A produced by LS7247. The LC2029 and LS7247 consortium showed a bactericidal effect on CJ strains. Co-cultivation of the consortium with CJ strains resulted in a decrease in the viability of the pathogen by 6 log. CFS from the LC2029 and LS7247 consortium prevented the growth of CJ-induced TLR4 mRNA expression in enterocytes. The LC2029 and LS7247 consortium inhibited a CJ-induced increase in IL-8 and TNF-α production in enterocytes, prevented CJ-induced intestinal barrier dysfunction, maintained the transepithelial electrical resistance of the enterocyte monolayers, and prevented an increase in intestinal paracellular permeability and zonulin secretion. CFS from the consortium stimulated IAP mRNA expression in enterocytes. The LC2029 and LS7247 consortium and the prebiotic Actigen represent a new synergistic synbiotic with anti-CJ properties that prevents intestinal barrier dysfunction and preserves intestinal homeostasis. Conclusions: These data highlight the potential of using a synergistic synbiotic as a preventive strategy for creating feed additives and functional nutrition products based on it to combat the prevalence of campylobacteriosis caused by MDR strains in animals and humans.

Quantitative assessment and genomic profiling of Campylobacter dynamics in poultry processing: a case study in the United Arab Emirates integrated abattoir system

In the United Arab Emirates, no previous research has investigated the dynamics of the foodborne pathogen Campylobacter in broiler abattoir processing. This study conducted in one of the largest poultry producers in the UAE, following each key slaughter stage-defeathering, evisceration, and final chilling-five broiler carcasses were collected from 10 slaughter batches over a year. Additionally, one caecum was obtained from 15 chickens in each slaughter batch to evaluate the flock colonization. In total, 300 samples (150 carcasses and 150 caeca) were collected and enumerated for Campylobacter using standard methods. Campylobacter was pervasive in caecal samples from all slaughter batches, with 86% of carcasses post-defeathering and evisceration stages and 94% post-chilling tested positive for Campylobacter. Campylobacter coli predominates in 55.2% of positive samples, followed by Campylobacter jejuni in 21%, with both species co-existing in 23.8% of the samples. Campylobacter counts in caecal contents ranged from 6.7 to 8.5 log10 CFU/g, decreasing post-defeathering and evisceration to 3.5 log10 CFU/g of neck skin and further to 3.2 log10 CFU/g of neck skin post-evisceration. After chilling, 70% of carcasses exceeded 3 log10 CFU/g of neck skin. Whole-genome sequencing (WGS) of 48 isolates unveiled diverse sequence types and clusters, with isolates sharing the same clusters (less than 20 single nucleotide polymorphisms) between different farms, different flocks within the same farm, as well as in consecutive slaughter batches, indicating cross-contamination. Multiple antimicrobial resistance genes and mutations in gyrA T86I (conferring fluoroquinolone resistance) and an RNA mutation (23S r.2075; conferring macrolide resistance) were widespread, with variations between C. coli and C. jejuni. WGS results revealed that selected virulence genes (pglG, pseD, pseI, flaA, flaB, cdtA, and cdtC) were significantly present in C. jejuni compared to C. coli isolates. This study offers the first insights into Campylobacter dynamics in poultry processing in the UAE. This work provides a base for future research to explore additional contributors to Campylobacter contamination in primary production. In conclusion, effective Campylobacter management demands a comprehensive approach addressing potential contamination sources at every production and processing stage, guided by continued microbiological surveillance and genomic analysis to safeguard public health and food safety.